Antibody testing will enhance the power and accuracy of COVID-19-prevention trials

M. Lipsitch, R. Kahn, M. Mina

Nature Medicine, 2020

Researchers starting clinical trials of prevention measures for COVID-19 have a unique window of opportunity for collecting blood from the participants, at baseline and at the end of the trial, to be able to incorporate critical data into their analysis once serological tests for the causative coronavirus become available.

Cited by 20 publications.

Field of study: Medicine

10.1038/s41591-020-0887-3